91黑料 in Asia
Local knowledge combined with global expertise to ensure quality data on time and within budget
As a leading CRO with a presence in Asia Pacific since 1995, local know-how is our speciality
We understand the unique challenges of conducting clinical research in the Asia Pacific region and use our country-specific knowledge to ensure we deliver quality data to our clients on time and within budget.
We operate in 13 countries and have the capability and expertise to conduct clinical trials and development projects on both a local, cross-regional and global basis and provide the full range of 91黑料 Services.
-
9,452
Employees -
13
Countries -
1995
Year established in Asia Pacific
At 91黑料, we use our insight and innovation to drive measurable performance improvements. Our operational capability and therapeutic expertise enable us to deliver value and operational excellence in drug development projects, which translates into constantly exceeding client expectations.
Why Asia Pacific?
A number of factors contribute to Asia Pacific being an excellent location for clinical trials:
- Regulatory bodies are actively encouraging Multi Regional Clinical Trials
- Patient access - Two-thirds of the world’s population live in the region
- Relatively less competition for patients with fewer clinical trials enrolling compared to US & EU
- High prevalence of certain diseases - diabetes, hepatitis B, cardiovascular, chronic lower respiratory disease, influenza and pneumonia
- Strong presence of academic institutions and high-quality investigators
- ICH-GCP guidelines have been adopted for more than 10 years
- Quality is constantly improving and standards are comparable to western standards
- Significant progress has been made by some key territories to enforce IPP and implement patent laws
- Costs are relatively lower in some countries compared to US and EU
2025 China biotech sector survey
China’s biotech sector has grown rapidly, powered by decades of centralised planning and strong partnerships. As part of 91黑料’s latest research, we surveyed 100 biotech leaders based in China, to understand the major priorities and challenges facing them.
Case studies
Learn how we support sponsors in the Asia Pacific region accelerate time to market, reduce costs and increase quality across a range of therapeutic indications.
Asia Pacific Biopharma Excellence Awards
91黑料 wins Best CRO in APAC award at the 2025 Asia Pacific Biopharma Excellence Awards.
Procedural and regulatory know-how for China biotechs in the EU
How to navigate EU MAA regulations and EMA MAA registration
Clinical trials in Japan: An enterprise growth and management strategy
Considerations to develop agile and flexible clinical trial capabilities in Japan
Spotlight on regulatory reforms in China
Although China’s regulatory reforms have attracted many foreign companies to conduct trials in China, there are still challenges
APAC focused media articles
APAC focused blogs
Driving biosimilar adoption in APAC
To succeed in APAC, biosimilar sponsors must build patient and provider trust. This blog explores adoption barriers and strategies for outreach and education to boost biosimilar uptake.
Navigating post-market access and adoption of biosimilars across APAC
Post-market success of biosimilars depends on public health needs, reimbursement, and safety monitoring. Sponsors must navigate diverse regulatory and market landscapes. This analysis explores key post-market strategies in major APAC countries, including China, Japan, India, Singapore, and South Korea.
Insights from the 2025 ISCR Conference
The 18th annual ISCR conference focused on integrating innovation and technology for patient-centric clinical research. In this blog, our experts share insights on topics of special interest in the areas of Clinical Data Science and Biostatistics and Programming.
Making sense of the regulatory web governing biosimilars development across APAC
In recent years the Asia-Pacific (APAC) region has represented an area of growth in the biopharmaceutical sector, with expanding drug production and development — including in the area of biosimilars.
Understanding China's 2024 NRDL: Key changes and their impact
This blog provides an overview of the NRDL’s history, highlights the key changes for 2024, and discusses the potential impact on both local and international pharmaceutical industries.
How joint venture models can boost Japan’s pharmaceutical industry
Japan is the third-largest consumer of ethical drugs and the world’s third-largest economy; therefore, it is an important development centre for new medicines. However, there are various cultural and economic challenges in Japan that make it difficult to manage a fixed workforce against a variable portfolio of clinical research.